WEgovy Real World Assessment of Weight Loss in Korea

Novo Nordisk

Status: Invitation-only

Conditions: Obesity

Treatments: Drug: Semaglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT07280221

NN9536-7850

U1111-1306-1595 (Other Identifier)

Details and patient eligibility

About

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Enrollment: 500 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
4. Male or female, aged ≥ 19 years at the time of signing the informed consent.

Exclusion criteria

1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Trial design

500 participants in 1 patient group

Once weekly Wegovy

Description:

Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

Treatment:

Drug: Semaglutide